Abstract
Specific blocking of interactions between ligands and receptors along the angiogenic pathways represents an effective approach for enhancing the efficacy as well as reducing adverse effects of chemotherapy. Over the past decade, there was a rapid progression in the application of this therapeutic strategy in cancer treatment. Anti-angiogenic therapy is the most promising targeted therapy for ovarian cancer. The addition of bevacizumab to conventional chemotherapy, either in the first-line setting or at disease relapse, may improve overall survival (OS) of ovarian cancer patients, at least in a subset of patients with poor prognosis. In this article, we summarize published data on the major agents used for anti-angiogenic therapy in ovarian cancers. We will review the molecular mechanisms, results of clinical trial of existing agents and describe the development of new agents. The limitations and side effects of angiogenesis inhibitor are also discussed.
Keywords: Ovarian cancer, molecular targeting, anti-angiogenic agents, angiogenesis, cancer therapy, inhibitor.
Current Drug Targets
Title:Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors
Volume: 18 Issue: 10
Author(s): Ping Duan, Lili Fan, Quansheng Gao, Bal Mukunda Silwal, Mulan Ren, Yang Shen*Wanglei Qu*
Affiliation:
- Department of Obstetrics and Gynecology, Zhongda Hospital, Southeast University, Nanjing 210009,China
- Department of Obstetrics and Gynecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027,China
Keywords: Ovarian cancer, molecular targeting, anti-angiogenic agents, angiogenesis, cancer therapy, inhibitor.
Abstract: Specific blocking of interactions between ligands and receptors along the angiogenic pathways represents an effective approach for enhancing the efficacy as well as reducing adverse effects of chemotherapy. Over the past decade, there was a rapid progression in the application of this therapeutic strategy in cancer treatment. Anti-angiogenic therapy is the most promising targeted therapy for ovarian cancer. The addition of bevacizumab to conventional chemotherapy, either in the first-line setting or at disease relapse, may improve overall survival (OS) of ovarian cancer patients, at least in a subset of patients with poor prognosis. In this article, we summarize published data on the major agents used for anti-angiogenic therapy in ovarian cancers. We will review the molecular mechanisms, results of clinical trial of existing agents and describe the development of new agents. The limitations and side effects of angiogenesis inhibitor are also discussed.
Export Options
About this article
Cite this article as:
Duan Ping, Fan Lili, Gao Quansheng, Silwal Mukunda Bal, Ren Mulan, Shen Yang*, Qu Wanglei*, Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors, Current Drug Targets 2017; 18 (10) . https://dx.doi.org/10.2174/1389450118666170329095807
DOI https://dx.doi.org/10.2174/1389450118666170329095807 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Innovative Drug Delivery Systems for the Administration of Natural Compounds
Current Bioactive Compounds Benchmarking Classification Models for Cell Viability on Novel Cancer Image Datasets
Current Bioinformatics Comprehensive Review of Cancer Chemopreventive Agents Evaluated in Experimental Carcinogenesis Models and Clinical Trials
Current Medicinal Chemistry Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Statins and Cancer
Anti-Cancer Agents in Medicinal Chemistry A Review of Ensemble Methods in Bioinformatics
Current Bioinformatics Personalized Peptide Vaccine for Treatment of Advanced Cancer
Current Medicinal Chemistry Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle
Current Medicinal Chemistry Chemistry and Biology of Secondary Metabolites from Aspergillus Genus
The Natural Products Journal Cardiovascular and Renal Complications of Type 2 Diabetes in Obesity:Role of Sympathetic Nerve Activity and Insulin Resistance
Current Diabetes Reviews Synthesis and In Vitro Antitumor Effect of New Vindoline-steroid Hybrids
Current Organic Chemistry Cell Biological Consequences of Mitochondrial NADH: Ubiquinone Oxidoreductase Deficiency
Current Neurovascular Research Structural Comparison of the Interaction of Tubulin with Various Ligands Affecting Microtubule Dynamics
Current Cancer Drug Targets Modulation of Notch Signaling as a Therapeutic Approach for Liver Cancer
Current Gene Therapy Serine Kinases as New Drug Targets for the Treatment of Type 2 Diabetes
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Anti-tumoral Titanium<sup>(IV)</sup> Complexes Stabilized with Phenolato Ligands and Structure-Activity Relationship
Current Topics in Medicinal Chemistry MicroRNA, a Promising Biomarker for Breast and Ovarian Cancer: A Review
Current Protein & Peptide Science Isothiocyanate Synthetic Analogs: Biological Activities, Structure-Activity Relationships and Synthetic Strategies
Mini-Reviews in Medicinal Chemistry Synthetic Approaches for Pyranoquinolines: A Concise Review
Current Organic Chemistry Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry